Which is more enduring - FAME or COURAGE?

New England Journal of Medicine

Volumn 367, Issue 11, 2012, Pages 1059-1061

  Boden, William E ^a,b  

^a STRATTON VA MEDICAL CENTER   (United States)

^b ALBANY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGRAPHY; CAUSE OF DEATH; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; EDITORIAL; EVIDENCE BASED MEDICINE; FRACTIONAL FLOW RESERVE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVASCULARIZATION; RISK ASSESSMENT; RISK FACTOR; SYNDROME DELINEATION; TREATMENT PLANNING; TREATMENT RESPONSE;

EID: 84866136251     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1208620     Document Type: Editorial

References (12)

1. Grüntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet 1978;1:263-6.
2. Pijls NHJ, van Son JA, Kirkeeide RL, De Bruyne B, Gould KL. Experimental basis of determining maximum coronary, myocardial, and collateral blood flow by pressure measurements for assessing functional stenosis severity before and after percutaneous transluminal coronary angioplasty. Circulation 1993;87:1354-67.
3. De Bruyne B, Pijls NHJ, Paulus WJ, Vantrimpont PJ, Sys SU, Heyndrickx GR. Transstenotic coronary pressure gradient measurement in humans: in vitro and in vivo evaluation of a new pressure monitoring angioplasty guide wire. J Am Coll Cardiol 1993;22:119-26.
4. Tonino PAL, De Bruyne B, Pijls NHJ, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 2009;360:213-24.
5. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356:1503-16.
6. The BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009;360:2503-15.
7. De Bruyne B, Pijls NHJ, Kalesan B, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med 2012;367:991-1001.
8. Levine GN, Bates ER, Blankenship JC, et al. 2011ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011;124(23):e574-e651. [Erratum, Circulation 2012;125(8):e412.]
9. Katritsis DG, Ioannidis JP. Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: a meta-analysis. Circulation 2005;111:2906-12.
10. Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, Nallamothu BK, Kent DM. Percutaneous coronary interventions for non-acute coronary artery disease: a quantitative 20-year synopsis and network meta-analysis. Lancet 2009;373:911-8. [Erratum, Lancet 2009;374:378.]
11. Stergiopoulos K, Brown DL. Initial coronary stent implantation with medical therapy vs medical therapy alone for stable coronary artery disease: meta-analysis of randomized controlled trials. Arch Intern Med 2012;172:312-9.
12. Boden WE. Mounting evidence for the lack of PCI benefit in stable ischemic heart disease: what more will it take to turn the tide of treatment? Comment on "initial coronary stent implantation with medical therapy vs medical therapy alone for stable coronary artery disease." Arch Intern Med 2012;172:319-21.